Metabolic syndrome in Iranian elderly
Nizal Sarrafzadegan1, Mojgan Gharipour, Masoumeh Sadeghi
1Professor, Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atherosclerosis
|December 4, 2012
Summary
Metabolic syndrome is highly prevalent in Iranian elderly, particularly women over 60. Early detection and management are crucial to prevent further health complications in this high-risk demographic.
Area of Science:
- Gerontology
- Public Health
- Epidemiology
Background:
- Investigating the prevalence of metabolic syndrome in Iranian elderly compared to middle-aged adults.
- Highlighting the need for age-specific health assessments.
Purpose of the Study:
- To compare the prevalence of metabolic syndrome and its components between Iranian elderly and middle-aged populations.
- To identify demographic and clinical factors associated with metabolic syndrome in different age groups.
Main Methods:
- Cross-sectional study utilizing data from the Isfahan Healthy Heart Program.
- Multistage cluster random sampling of residents over 19 years old.
- Data collection included questionnaires, anthropometric measurements, blood pressure, and biochemical analyses.
Main Results:
- Metabolic syndrome prevalence was significantly higher in individuals over 60 (49.5%) compared to those under 60 (17.5%).
- Elderly females exhibited a higher prevalence (59.2%) than elderly males (39.8%).
- Significant differences in anthropometric measures and biochemical parameters were observed between elderly and younger populations, especially in women.
Conclusions:
- Metabolic syndrome is highly prevalent in the Iranian elderly, with a notable higher occurrence in women.
- Recommends early diagnosis and management strategies for metabolic syndrome in elderly individuals to mitigate risks of subsequent complications.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...